AGO TUMOR NO FURTHER A MYSTERY

Hormonal therapy remains the procedure of initial option for metastatic individuals with endocrine-responsive breast cancer (LoE 1a A, In the past ++). The sequential use in the offered medication relies on the individual pretreatment. Reassessment of ER, PR, and HER2 in tumor tissue at time of diagnosis of relapse is usually recommended When doabl